ly3437943 retatrutide triple agonist glp-1 gip glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% LY3437943, a novel triple glucagon,

This is where a systems approach becomes relevant: supporting mitochondrial function, redox balance, and recovery capacity can matter even when requirements are technically met

Start low at 50 mg per day to assess tolerance, then titrate up to 100 mg if well tolerated

, ,

CagriSema submitted for FDA approval in December 2025 with expected approval in Q4 2026 or Q1 2027, meaning launch around mid-2027

It may help to increase the utilization of fatty acids as an energy source, which could contribute to weight loss efforts

How to Take Them (and Combine If Desired) L-theanine Usage: Take 100-200 mg once or twice daily, with or without food